Clinical trials: Melanoma Cancer
Dose Escalation: Relapsed/Refractory Solid Tumor Malignancies or Lymphoma, Dose Expansion: Triple Negative Breast Cancer, HNSCC, Non-Hodgkins, Urothelial Cancer, Immune Checkpoint Refractory Melanoma, and NSCLC Lymphoma
Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Participants in Advanced Malignancies
The clinical study will assess the safety and tolerability of escalating intratumoral doses of mRNA-2752 in participants with relapsed/refractory solid tumor malignancies or lymphoma.
- Trial name
- NCT03739931
- Testing
- mRNA-2752, Durvalumab
- Where
- 24 sites in United States, Australia and 1 more
- Volunteers
- 134 people
- Sponsor
- ModernaTX, Inc.
Nodular Basal Cell Carcinoma of Skin
Photodynamic Therapy Associated With Sonodynamic Therapy for the Treatment of Nodular Basal Cell Carcinoma
Evaluation of a therapeutic protocol based on the combination of photodynamic therapy and sonodynamic therapy, referred to as sonophotodynamic therapy.
- Trial name
- NCT07381972
- Testing
- Control Arm (Conventional Therapy), Experimental arm
- Where
- Brazil
- Volunteers
- 142 people
- Sponsor
- University of Sao Paulo
Melanoma
Real-world Outcomes Among Patients With Melanoma Treated With Neoadjuvant Nivolumab+Relatlimab or Nivolumab+Ipilimumab
The purpose of this study is to understand the characteristics of adults diagnosed with with clinically palpable stage III resectable melanoma, the associated treatment patterns for their disease, and outcomes associated with the…
- Trial name
- NCT07091695
- Testing
- Nivolumab + relatlimab, Nivolumab + ipilimumab
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Bristol-Myers Squibb
Colorectal Cancer, Ovarian Cancer
Autologous and Allogeneic Whole Cell Cancer Vaccine for Metastatic Tumors
This study is based on the finding that tumor cells that are grown in the laboratory can be modified in such a way that, when injected to the patient, they will stimulate his/her immune response.
- Conditions
- Colorectal Cancer, Ovarian Cancer, Gastric Cancer, Breast Cancer
- Trial name
- NCT00722228
- Testing
- Autologous or Allogeneic tumor cells
- Where
- Israel
- Volunteers
- 50 people
- Sponsor
- Hadassah Medical Organization
Melanoma, Skin Melanoma
Differential Risks for Melanoma: p16 and DNA Repair
The goal of this study is to find out if some people are more likely to get melanoma, a form of skin cancer, than others. People respond to the environment in different ways.
- Trial name
- NCT00615095
- Testing
- self-administered questionnaire and blood draw, health questionnaire, blood draw and skin exam
- Where
- United States
- Volunteers
- 323 people, healthy volunteers welcome
- Sponsor
- Memorial Sloan Kettering Cancer Center
Penile Cancer, Inguinal Lymphadenopathy
VideoEndoscopic Radical Inguinal Lymphadenectomy for Penile Cancer
Assess the feasibility of performing a RCT comparing videoendoscopic radical inguinal lymphadenectomy versus open radical inguinal lymphadenectomy in men diagnosed with genital cancer requiring inguinal lymphadenectomy, and…
- Conditions
- Penile Cancer, Inguinal Lymphadenopathy, Melanoma
- Trial name
- VELRAD (NCT05592639)
- Testing
- Videoendoscopic radical inguinal lymphadenectomy or open radical inguinal lymphadenectomy
- Where
- United Kingdom
- Volunteers
- 50 people
- Sponsor
- University College, London
Malignant Melanoma, Head and Neck Cancer
Tissue and Hematopoietic/Mesenchymal Stem Cell for Humanized Xenograft Studies in Melanoma and Squamous Head and Neck Cancer
The overall goal of this study is to develop a pre-clinical platform of melanoma and head and neck squamous cell cancer that will allow the investigators to learn more about these diseases and discover better and more…
- Trial name
- NCT02331134
- Testing
- Filgrastim
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- University of Colorado, Denver
Melanoma
18F-Labeled Picolinamide PET Imaging of Melanoma Diagnosis
The purpose of this study is to assess the dosimetric properties of the positron emission tomography (PET) imaging probe 18F labeled Picolinamide (18F-P3BZA) and preliminarily evaluate its diagnosis value in melanoma patients.
- Trial name
- NCT03033485
- Testing
- 18F-P3BZA
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Xijing Hospital
Melanoma (Skin)
Oblimersen and Dacarbazine in Treating Patients With Advanced Malignant Melanoma That Has Responded to Treatment on Clinical Trial GENTA-GM301
RATIONALE: Drugs used in chemotherapy, such as dacarbazine, use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00070343
- Testing
- oblimersen sodium, dacarbazine
- Where
- United States
- Sponsor
- Jonsson Comprehensive Cancer Center
Clinical Stage III Cutaneous Melanoma AJCC v8, Melanoma
Intra-Lymphatic STI-3031 Using the Sofusa DoseConnect Device for Treatment of In-Transit Melanoma, The Sofusa-2 Study
This phase Ib trial tests the safety, side effects, and best dose of STI-3031 given directly into the into the lymph nodes or the lymph vessels (intra-lymphatic) using the Sofusa DoseConnect device in treating patients with…
- Conditions
- Clinical Stage III Cutaneous Melanoma AJCC v8, Melanoma, Metastatic Melanoma, Recurrent Metastatic Melanoma
- Trial name
- NCT05393713
- Testing
- Anti-PD-L1 Monoclonal Antibody IMC-001, Punch Biopsy
- Where
- 2 sites in United States
- Volunteers
- 3 people
- Sponsor
- Mayo Clinic
Melanoma
A Study of Patients Receiving Adjuvant Nivolumab Therapy for Melanoma That Has Been Removed
An observational study of melanoma participants who are eligible for and who have initiated treatment with adjuvant nivolumab as part of routine clinical practice.
- Trial name
- NCT03771859
- Where
- 14 sites in Belgium, Luxembourg
- Volunteers
- 152 people
- Sponsor
- Bristol-Myers Squibb
Phase 1, Recurrent Melanoma
Phase 1 Dose Escalation and Expansion Study of PRAME T Cell Receptor (TCR) Engineered NK Cells in Participants With Recurrent and/or Refractory Melanoma (PRAMETIME-Mel)
To find the highest tolerable dose and recommended dose of PRAME-TCR-NK cells that can be given to participants with recurrent and/or refractory melanoma. The safety and tolerability of PRAME-TCR-NK cells will also be studied.
- Conditions
- Phase 1, Recurrent Melanoma, Refractory Melanoma
- Trial name
- NCT06660420
- Testing
- Cyclophosphamide, Fludarabine
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- M.D. Anderson Cancer Center
Glioblastoma, Melanoma Stage IV
A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors
This is an open-label, two-part, phase 1-2 dose-finding study designed to determine the safety, tolerability, PK, PD, and proof-of-concept efficacy of ST101 administered IV in patients with advanced solid tumors.
- Conditions
- Glioblastoma, Melanoma Stage IV, Breast Cancer, Prostate Cancer
- Trial name
- NCT04478279
- Testing
- ST101, Temozolomide, Radiation
- Where
- 11 sites in United States, United Kingdom
- Volunteers
- 125 people
- Sponsor
- Sapience Therapeutics
Brain Metastases, Glioma of Brain
Precise DCE-MRI in Diagnosing Participants With Recurrent High Grade Glioma or Melanoma Brain Metastases
Dynamic contrast-enhanced (DCE) magnetic resonance imaging (MRI) is a potentially powerful diagnostic tool for the management of brain cancer and other conditions in which the blood-brain barrier is compromised.
- Conditions
- Brain Metastases, Glioma of Brain, Brain Tumor, Metastatic Melanoma
- Trial name
- NCT03698162
- Testing
- Dynamic Contrast-Enhanced Magnetic Resonance Imaging, Bevacizumab Injection
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of Southern California
Acute Myeloid Leukemia, Melanoma
PET Imaging of Cancer Patients Using 68Ga-DOTA-Siglec-9
This is a scientific study to determine expression of vascular adhesion protein 1 (VAP-1) in cancer patients by 68Ga-DOTA-Siglec-9 positron emission tomography/computed tomography (PET/CT) before and after cancer treatment.
- Conditions
- Acute Myeloid Leukemia, Melanoma, Non Small Cell Lung Cancer
- Trial name
- CANSI (NCT05212103)
- Where
- Finland
- Volunteers
- 30 people
- Sponsor
- Turku University Hospital
Melanoma
Trametinib With GSK2141795 in BRAF Wild-type Melanoma
This is a multicenter phase II clinical study of trametinib in combination with GSK2141795 in patients with BRAF wild-type mutation melanoma.
- Trial name
- NCT01941927
- Testing
- Trametinib (GSK1120212), GSK2141795
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Adil Daud
Neuroblastoma, Melanoma
A Phase I Trial Of The Humanized Anti-GD2 Antibody In Children And Adolescents With Neuroblastoma, Osteosarcoma, Ewing Sarcoma and Melanoma
Relapsed and/or refractory neuroblastoma, osteosarcoma, Ewing sarcoma and melanoma are considered difficult to treat and cure. For this study we are testing the use of a new experimental (investigational) antibody called…
- Conditions
- Neuroblastoma, Melanoma, Osteosarcoma, Ewing Sarcoma
- Trial name
- NCT00743496
- Testing
- Anti-GD2 antibody
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- St. Jude Children's Research Hospital
Malignant Melanoma
Observational Study for Melanoma Adjuvant Treatment With Tafinlar® + Mekinist® (Dabrafenib + Trametinib)
The primary objective for this non-interventional study was to assess the quality of life of melanoma patients under adjuvant treatment with dabrafenib and trametinib in real world setting in Portugal through disease specific…
- Trial name
- NCT04547946
- Testing
- dabrafenib + trametinib
- Where
- 2 sites in Portugal
- Volunteers
- 3 people
- Sponsor
- Novartis Pharmaceuticals
Advanced Cancer, Solid Tumors
Sodium Stibogluconate With Interferon Alpha-2b for Patients With Advanced Malignancies
Primary Objective: -To determine the maximum tolerated dose (MTD) and dose limiting toxicity (DLT) of SSG in combination with IFN alpha2b in patients with advanced malignancies.
- Trial name
- NCT00629200
- Testing
- Sodium Stibogluconate, Interferon Alpha-2b
- Where
- 2 sites in United States
- Volunteers
- 33 people
- Sponsor
- M.D. Anderson Cancer Center
Advanced Unresectable Melanoma, Metastatic Melanoma
Mirdametinib in Patients With Advanced NF1-mutant Melanoma
The goal of this clinical trial is to evaluate clinical efficacy of mirdametinib in patients with advanced NF1-mutant melanoma whose disease has progressed while on or after previous immunotherapy.
- Trial name
- NCT07237100
- Testing
- Mirdametinib
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Kevin Kim, MD